Jamie Hawley’s Post

Please share these stories with anyone suffering from Lung disease. We don't just share stories but also real science behind this glutathione precursor. CASE STUDY / Lung deterioration , now published in the medical journal CHEST referred to by many Respirologists With a background in law from her native France, Nona became actively involved with business and philanthropological pursuits in Canada. She was a 41-year-old mother of three suffering from Hodgkin’s disease and requiring both chemotherapy and radiotherapy. Although these treatments cured her of Hodgkin’s disease, the treatments left her lungs scarred – the condition of pulmonary fibrosis. Her interests had to be dropped as her breathing deteriorated. She ended up staying at home, using home oxygen and many medications. Despite all interventions, her pulmonary function tests (PFT’s) continued to fall. After six weeks of Immunocal 20 grams/day she went back to her pulmonary doctor, claiming she could breath again. Thinking there might be a placebo effect; the physician repeated her pulmonary function tests, which showed her back at about 90% of normal values. To eliminate other possibilities, the Immunocal was withdrawn. She subsequently deteriorated again. Three weeks after reinstating the Immunocal, her PFT’s went back up to 95% of normal values. She promised herself never to stop again. #lungdisease #asthma #COPD #glutathione #glutathioneprecursor #interstiallungdisease #immunesystem #respirologist #immunetherapy www.immunotec.com/possom      

Each area of advancement, from precision medicine to immunology to cell and gene therapy, faces unique access barriers. Join experts from MMIT and The Dedham Group for an in-depth webinar on how pharma companies can address these barriers: https://ow.ly/jv9050RIWJ9.

Chronic Venous Insufficiency Market Growth Anticipated by 2034 | Companies includes Verigraft, MediWound, TissueTech, Amniox Medical: Chronic Venous Insufficiency Market Several factors are expected to accelerate the growth of the Chronic Venous Insufficiency market during the forecast period (2023–2034). Increased awareness about available treatments, rising disease prevalence, and heightened disease awareness are key drivers. In the … Continue reading → #Business #Europe #HealthMedicine #PharmaceuticalsBiotech #US

Our latest episode is about digital therapeutics and what we can expect in the future. It also cover a very interesting report from MHRA and NICE on digital health apps used in patients with mental health and feedback from users and specialists. #digitalhealth #trends #mentalhealth

Each area of advancement, from precision medicine to immunology to cell and gene therapy, faces unique access barriers. Join experts from MMIT and The Dedham Group for an in-depth webinar on how pharma companies can address these barriers: https://ow.ly/vyIL50RIY80.

Our latest episode is out! You can learn about digital health trends and the chances to find funding in this area. It also covers MHRA and NICE report on digital health solutions in mental health. It is very interesting to hear what users think of digital health applications. #digitalhealth #mentalhealth

Rare disease drug development is thriving – thanks to promising gene therapies, advances in AI and a supportive regulatory environment, among other influences. But more work needs to be done, urgently. 🎙 Listen to the latest episode of our podcast series "Preparing for a Cell and Gene Future," as Jamie Pierson and Kim MacDonnell address the use and regulatory acceptance of surrogate endpoints to demonstrate clinical benefit:

Rare disease drug development is thriving – thanks to promising gene therapies, advances in AI and a supportive regulatory environment, among other influences. But more work needs to be done, urgently. 🎙 Listen to the latest episode of our podcast series "Preparing for a Cell and Gene Future," as Jamie Pierson and Kim MacDonnell address the use and regulatory acceptance of surrogate endpoints to demonstrate clinical benefit:

Mom didn't know the drug wouldn't work for her. The doctor just prescribed "the protocol". One size does NOT fit all. After Mom's cancer was removed, she was prescribed tamoxifen per the 5-year protocol. Back in 2007, no genetic testing was done to determine drug compatibility. When I ran a Pharmacogenomic (PGx) test using her DNA in 2022, we learned that her body did not break down tamoxifen efficiently and she received NO benefit from the drug. I would definitely recommend a test for anyone who has not already been tested. It could be difference between life and death. And if you have been tested, ask for the results and share them with ALL your medical providers. Keep a copy of the results on your phone and/or in your medical notebook. If you don't understand your results, I can help with that! www.qrxconsults.com

Today, we announced positive interim data from our ongoing Phase 2 trial evaluating the safety and efficacy of our product candidate in people with #ChronicNeutropenia (CN). We also announced that we’ve started screening patients for enrollment into our pivotal Phase 3 trial, the 4WARD study, to evaluate our product candidate in people with congenital, acquired primary autoimmune, or idiopathic CN.   We’re hosting a webinar today at 8:00 am ET and will detail the interim results, feature clinical experts in the treatment of CN, and discuss the 4WARD study.   Learn more here: https://lnkd.in/eaDtEtT6 #Progress4Patients